calcineurin

However, PTHL is a distinct clinical entity, which is associated with the use of calcineurin inhibitors, such as cyclosporine, and other mediators of the rejection process such as sirolimus.

Cependant, la PTHL est une entité clinique distincte associée à l'utilisation d’ inhibiteurs de calcineurine, tels que la ciclosporine, et d'autres médiateurs du processus de rejet tels que le sirolimus.